SEARCH

SEARCH BY CITATION

References

  • 1
    Gaslightwala I, Bini EJ. Impact of HIV infection on the prevalence and severity of steatosis in patients with chronic HCV. J Hepatol 2006; 44: 1026-1032.
  • 2
    Castéra L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, et al. Hepatic steatosis in HIV-infected patients in France: comparison with HCV-monoinfected patients matched for BMI and genotype. Aliment Pharmacol Ther 2007; 26: 1489-1498.
  • 3
    Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, et al. Hepatic steatosis in HIV/HCV-coinfected patients: analysis of risk factors. AIDS 2006; 20: 525-531.
  • 4
    McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infections in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-372.
  • 5
    Sterling RK, Contos MJ, Smith PG, Stravitz RT, Luketic VA, Fuchs M, et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. HEPATOLOGY 2008; 47: 1118-1127.
  • 6
    Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585-592.
  • 7
    Marks KM, Petrovic LM, Talal H, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192: 1943-1949.
  • 8
    Blas-García A, Apostolova N, Ballesteros D, Monleón D, Morales JM, Rocha M, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. HEPATOLOGY 2010; 52: 115-125.
  • 9
    Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. HEPATOLOGY 2005; 42: 310-316.
  • 10
    Neau D, Winnock M, Castéra L, Bail BL, Loko MA, Géraut L, et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV. J Acquir Immune Defic Syndr 2007; 45: 168-173.
  • 11
    Rodríguez-Torres M, Govindarajan S, Solá R, Clumeck N, Lissen E, Pessôa M, et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy, and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48: 756-764.
  • 12
    Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a metaanalysis of the risk factors. HEPATOLOGY 2010; 52: 71-78.
  • 13
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
  • 14
    Pascual-Pareja JF, Camino A, Larrauri J, López-Diéguez M, Montes ML, González-García J, et al. Factors associated with hepatic steatosis in human immunodeficiency virus and hepatitis C virus coinfected patients. Med Clin 2009; 132: 208-213.
  • 15
    Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140: 809-817.
  • 16
    McGovern BH. Hepatis steatosis in HIV/HCV-coinfected patients: time to reevaluate! Gastroenterology 2011; 140: 772-775.
  • 17
    Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. HEPATOLOGY 2009; 50: 1056-1063.
  • 18
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastronterol 1999; 94: 2467-2474.
    Direct Link:
  • 19
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
  • 20
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
  • 21
    Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J, et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50: 797-804.
  • 22
    Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother 2009; 64: 901-909.
  • 23
    Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside, and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-1118.
  • 24
    Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of non alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. HEPATOLOGY 2004; 40: 820-826.
  • 25
    Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-2047.
    Direct Link:
  • 26
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
  • 27
    Rafiq N, Bai C, Fang Y, Shrishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.